Science Custom Publishing
Science Custom Publishing
Podcast Description
Hear from some of the greatest minds in science on a range of topics in conversation with editors from Science custom publishing.
Podcast Insights
Content Themes
The podcast delves into various topics related to advancements in biotechnology and oncology, with episodes focusing on innovations such as gene editing, the specifics of cell therapy for solid tumors, and the implications of these technologies for patient care, exemplified by conversations around AstraZeneca's efforts in this field.
Hear from some of the greatest minds in science on a range of topics in conversation with editors from Science custom publishing.
Progress in the development of cell therapies for the treatment of a range of diseases is accelerating, helped along by advancements in gene editing and manufacturing techniques. Pharmaceutical company AstraZeneca has been investing heavily in cell therapy technologies for the treatment of cancer, particularly solid tumors that pose distinct challenges, and is looking to make contributions to patient care.
In this podcast from the Science custom publishing office and funded by Astrazeneca, Senior Editor Erika Berg interviews Mark Cobbold, Senior Vice President of Discovery and the Head of Oncology Cell Therapy at AstraZeneca. They explore the future of cell therapy in cancer treatment, the science behind “living medicines,” and the vision of scalable, off-the-shelf cell therapies. This episode is a must-listen for anyone passionate about the future of oncology and personalized medicine.
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.